Edition:
United Kingdom

Aravive Inc (ARAV.OQ)

ARAV.OQ on NASDAQ Stock Exchange Global Select Market

5.30USD
18 Jul 2019
Change (% chg)

-- (--)
Prev Close
$5.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
5,075
52-wk High
$12.60
52-wk Low
$3.07

Latest Key Developments (Source: Significant Developments)

Aravive Biologics Initiates Phase 1b Portion Of Phase 1b/2 Clinical Trial Of AVB-S6-500 In Platinum-Resistant Recurrent Ovarian Cancer
Tuesday, 11 Dec 2018 

Dec 11 (Reuters) - Aravive Inc ::ARAVIVE BIOLOGICS INITIATES PHASE 1B PORTION OF PHASE 1B/2 CLINICAL TRIAL OF AVB-S6-500 IN PLATINUM-RESISTANT RECURRENT OVARIAN CANCER.ARAVIVE INC - ANTICIPATE MEASUREMENT OF CIRCULATING FREE GAS6 WILL BE HIGHLY USEFUL AS A BIOMARKER OF DRUG ACTIVITY IN NEW TRIAL.ARAVIVE INC - INITIAL PHASE 1 CLINICAL TRIAL OF AGENT IN HEALTHY VOLUNTEERS SHOWED A FAVORABLE SAFETY AND TOLERABILITY PROFILE.ARAVIVE INC - NO REPORTED SERIOUS ADVERSE EVENTS AND NO ADVERSE EVENTS THAT LIMITED DOSING IN TRIAL.  Full Article

Aravive Qtrly Loss Per Share $1.08
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Aravive Inc ::ARAVIVE INC QTRLY LOSS PER SHARE $1.08.ARAVIVE INC - CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS WERE $62.6 MILLION AS OF SEPTEMBER 30, 2018.  Full Article

Versartis Q4 Earnings Per Share $0.87
Thursday, 1 Mar 2018 

March 1 (Reuters) - Versartis Inc ::VERSARTIS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 EARNINGS PER SHARE $0.87.‍CONTRACT REVENUE FOR QUARTER AND YEAR ENDED DECEMBER 31, 2017 WAS $40.0 MILLION​.  Full Article

Advent Life Sciences Reports 4.5 Pct Passive Stake In Versartis Inc
Thursday, 8 Feb 2018 

Feb 8 (Reuters) - Versartis Inc ::ADVENT LIFE SCIENCES LLP REPORTS A 4.5 PERCENT PASSIVE STAKE IN VERSARTIS, INC. AS OF DEC 31, 2017 - SEC FILING.  Full Article

Versartis reports Q3 loss $1.40/shr
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Versartis Inc :Versartis reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $1.40.Q3 earnings per share view $-0.71 -- Thomson Reuters I/B/E/S.  Full Article

Versartis announces phase 3 Velocity trial of somavaratan in pediatric growth hormone deficiency did not meet primary endpoint
Thursday, 21 Sep 2017 

Sept 21 (Reuters) - Versartis Inc :Versartis announces phase 3 Velocity trial of somavaratan in pediatric growth hormone deficiency did not meet primary endpoint.Versartis Inc - Study ‍did not meet its primary endpoint of non-inferiority.​.Versartis Inc says ‍somavaratan was well tolerated with treatment discontinuation rate lower than for genotropin arm.​.Versartis Inc - ‍No new emergent safety signals were observed in the study​.  Full Article

Versartis Inc - files for mixed shelf offering of up to $500 million - SEC filing‍​
Monday, 7 Aug 2017 

Aug 7 (Reuters) - Versartis Inc :Versartis Inc - files for mixed shelf offering of up to $500 million - SEC filing‍​.  Full Article